R&D channel feed

Ab­b­Vie touts promis­ing PhI­II da­ta for Orilis­sa as ex­ecs line up their sec­ond pitch and ri­vals lay in wait

7 years ago

As­traZeneca’s big MYS­TIC tri­al ends a com­plete fail­ure as Imfinzi/treme­li­mum­ab com­bo flops on over­all sur­vival

7 years ago

Bol­stered by promis­ing PhI­Ib snap­shot, uniQure plays catch-up with Spark in the race to a he­mo­phil­ia B gene ther­a­py

7 years ago
Cell/Gene Tx

The sand­box: Park­er In­sti­tute throws its re­search mus­cle be­hind gene ther­a­py tech for de­stroy­ing can­cer cells

7 years ago
Cell/Gene Tx

Elud­ed by clear suc­cess in esophageal car­ci­no­ma, Mer­ck touts sub­group OS win for Keytru­da

7 years ago

Did No­var­tis get $150M worth of pos­i­tive PhII car­dio da­ta from Akcea?

7 years ago

South Ko­re­an reg­u­la­tor sus­pends Sam­sung Bi­o­Log­ic­s' stock, cit­ing ac­count­ing vi­o­la­tions

7 years ago
Pharma

New can­cer tar­get? GSK high­lights on­col­o­gy am­bi­tions with its move in­to the clin­ic with RIP1 drug for pan­cre­at­ic can­cer

7 years ago

As­traZeneca makes $1B-plus in cash-and-stock deal grant­i­ng So­bi US rights to RSV drug Synagis

7 years ago

Con­cert’s ini­tial alope­cia da­ta fall short against Pfiz­er, prompt­ing in­vestor blow back

7 years ago

No­var­tis builds block­buster case for En­tresto, beat­ing out a cheap ACE in­hibitor — or not

7 years ago

Amarin just rolled out a bat­tery of promis­ing new da­ta for Vas­cepa — brace your­self for the M&A chat­ter to come

7 years ago

#SITC18: An­oth­er un­der­whelm­ing per­for­mance for STING dam­ages Aduro’s al­ready suf­fer­ing share price

7 years ago

The lat­est up­date on NK­TR-214/Op­di­vo from Nek­tar and Bris­tol-My­ers will keep the con­tro­ver­sy burn­ing over the ORR rate

7 years ago

Genen­tech de­tails claims Sanofi part­ner JHL used stolen trade se­crets to de­vel­op ri­val drugs at an 'as­ton­ish­ing pace'

7 years ago
Pharma

In­novent, Eli Lil­ly cite a new suc­cess for their PD-1 in lung can­cer, with a like­ly pi­o­neer­ing ap­proval in Chi­na loom­ing

7 years ago
China

Ab­b­Vie hatch­es plans for a ma­jor new R&D hub close to its part­ners in Bay Area's buzzy Oys­ter Point

7 years ago
Pharma

Flail­ing Mer­ri­mack brings out the ax for an­oth­er big cut­back, lop­ping 60% of a shrink­ing crew as it hunts op­tions

7 years ago

Voy­ager's shares sink af­ter ex­ecs say FDA has re­versed course on an ac­cel­er­at­ed fil­ing for its gene ther­a­py

7 years ago

Eli Lil­ly sweeps the rest of the BACE work out of the pipeline fol­low­ing their lat­est ma­jor set­back on Alzheimer’s

7 years ago

Mo­ment of truth looms for Nek­tar, Bris­tol-My­ers with a ma­jor up­date to NK­TR-214 com­bo — and the lat­est snap­shot is not promis­ing

7 years ago

A star drug in Mallinck­rodt’s $1.2B Su­cam­po buy­out flops in piv­otal tri­al

7 years ago

Foamix claims goal-win­ning suc­cess in twin piv­otal stud­ies for rosacea — shares spike

7 years ago

On­coSec’s de­fense of weak pre­lim­i­nary Ta­vo da­ta for PD-1 re­sis­tant melanoma can’t stop a rout

7 years ago
First page Previous page 259260261262263264265 Next page Last page
A service from the Financial Times